ACTRN12610000432011尚未招募4 期
A randomised controlled trial of atomoxetine vs placebo for attentional lapses in adults with attention deficit hyperactivity disorder (ADHD)
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Aged at least 18 years
- •Diagnosis of ADHD
排除标准
- •1. Current or past diagnosis of psychotic disorders, pervasive development disorders, intellectual impairment,
- •2. History of serious neurologic illnesses including stroke, brain tumours, head trauma, multiple sclerosis, epilepsy, movement disorders or migraine in treatment
- •3. drug dependency on alcohol or illicit substances
- •4. Pregnancy or breast feeding
研究者
相似试验
招募中
2 期
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
已完成
不适用
Atomoxetine for attention deficit hyperactivity disorder (ADHD) in children with special educational needsAttention deficit hyperactivity disorder (ADHD), mental retardation (intellectual disability)Mental and Behavioural DisordersHyperkinetic disordersISRCTN25691213King's College London (UK)40
已完成
4 期
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)Reading DisorderAttention Deficit Hyperactivity DisorderNCT00191906Eli Lilly and Company121
进行中（未招募）
不适用
An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions - NDChild or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHDMedDRA version: 6.1Level: PTClassification code 10003736EUCTR2005-005701-32-ITELI LILLY300
招募中
2 期
Effectiveness of Atomoxetine treatment for methamphetamine use disorderOther stimulants dependence syndrome.Dependence syndrome: A cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despiteF15.24IRCT2017070234844N1Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research90